These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 31621043

  • 1. Observation after surgery for low grade glioma: long-term outcome in the light of the 2016 WHO classification.
    Jansen E, Hamisch C, Ruess D, Heiland DH, Goldbrunner R, Ruge MI, Schnell O, Grau SJ.
    J Neurooncol; 2019 Dec; 145(3):501-507. PubMed ID: 31621043
    [Abstract] [Full Text] [Related]

  • 2. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
    Tom MC, Park DYJ, Yang K, Leyrer CM, Wei W, Jia X, Varra V, Yu JS, Chao ST, Balagamwala EH, Suh JH, Vogelbaum MA, Barnett GH, Prayson RA, Stevens GHJ, Peereboom DM, Ahluwalia MS, Murphy ES.
    Int J Radiat Oncol Biol Phys; 2019 Dec 01; 105(5):1106-1112. PubMed ID: 31461674
    [Abstract] [Full Text] [Related]

  • 3. Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era.
    Tom MC, Varra V, Leyrer CM, Park DY, Chao ST, Yu JS, Suh JH, Reddy CA, Balagamwala EH, Broughman JR, Kotagal KA, Vogelbaum MA, Barnett GH, Ahluwalia MS, Peereboom DM, Prayson RA, Stevens GHJ, Murphy ES.
    Int J Radiat Oncol Biol Phys; 2019 Aug 01; 104(5):1099-1105. PubMed ID: 31022510
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C.
    Oncotarget; 2015 Oct 06; 6(30):30295-305. PubMed ID: 26210286
    [Abstract] [Full Text] [Related]

  • 7. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
    Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, Hess KR, Verhaak RGW.
    Neuro Oncol; 2017 Jun 01; 19(6):786-795. PubMed ID: 28340142
    [Abstract] [Full Text] [Related]

  • 8. Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas.
    Aoki K, Suzuki H, Yamamoto T, Yamamoto KN, Maeda S, Okuno Y, Ranjit M, Motomura K, Ohka F, Tanahashi K, Hirano M, Nishikawa T, Shimizu H, Kitano Y, Yamaguchi J, Yamazaki S, Nakamura H, Takahashi M, Narita Y, Nakada M, Deguchi S, Mizoguchi M, Momii Y, Muragaki Y, Abe T, Akimoto J, Wakabayashi T, Saito R, Ogawa S, Haeno H, Natsume A.
    Cancer Res; 2021 Sep 15; 81(18):4861-4873. PubMed ID: 34333454
    [Abstract] [Full Text] [Related]

  • 9. Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system.
    Delev D, Heiland DH, Franco P, Reinacher P, Mader I, Staszewski O, Lassmann S, Grau S, Schnell O.
    J Neurooncol; 2019 Jan 15; 141(1):223-233. PubMed ID: 30467813
    [Abstract] [Full Text] [Related]

  • 10. 18F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma.
    Cicone F, Carideo L, Scaringi C, Arcella A, Giangaspero F, Scopinaro F, Minniti G.
    Ann Nucl Med; 2019 Apr 15; 33(4):295-302. PubMed ID: 30607877
    [Abstract] [Full Text] [Related]

  • 11. Accelerated progression of IDH mutant glioma after first recurrence.
    Miller JJ, Loebel F, Juratli TA, Tummala SS, Williams EA, Batchelor TT, Arrillaga-Romany I, Cahill DP.
    Neuro Oncol; 2019 May 06; 21(5):669-677. PubMed ID: 30668823
    [Abstract] [Full Text] [Related]

  • 12. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
    Yamauchi T, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, Kitagawa Y, Kondo E, Tsushita N, Satomi K, Yoshida A, Ichimura K, Narita Y.
    Brain Tumor Pathol; 2018 Jul 06; 35(3):148-158. PubMed ID: 29922974
    [Abstract] [Full Text] [Related]

  • 13. Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma.
    Choi J, Kim SH, Ahn SS, Choi HJ, Yoon HI, Cho JH, Roh TH, Kang SG, Chang JH, Suh CO.
    Sci Rep; 2020 Feb 07; 10(1):2086. PubMed ID: 32034238
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.
    Patel SH, Bansal AG, Young EB, Batchala PP, Patrie JT, Lopes MB, Jain R, Fadul CE, Schiff D.
    AJNR Am J Neuroradiol; 2019 Jul 07; 40(7):1149-1155. PubMed ID: 31248860
    [Abstract] [Full Text] [Related]

  • 16. Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma.
    Liu Z, Zhang T, Jiang H, Xu W, Zhang J.
    Acad Radiol; 2019 Aug 07; 26(8):1062-1070. PubMed ID: 30393056
    [Abstract] [Full Text] [Related]

  • 17. Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas.
    Franceschi E, Tosoni A, Bartolini S, Minichillo S, Mura A, Asioli S, Bartolini D, Gardiman M, Gessi M, Ghimenton C, Giangaspero F, Lanza G, Marucci G, Novello M, Silini EM, Zunarelli E, Paccapelo A, Brandes AA.
    Eur J Cancer; 2020 Sep 07; 137():10-17. PubMed ID: 32721633
    [Abstract] [Full Text] [Related]

  • 18. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O, Carrato C, de Aguirre I, Queralt C, Muñoz A, Ramirez JL, Rosell R, Villà S, Diaz R, Estival A, Teixidor P, Indacochea A, Ahjal S, Vilà L, Balañá C.
    J Neurooncol; 2017 Nov 07; 135(2):273-284. PubMed ID: 28884377
    [Abstract] [Full Text] [Related]

  • 19. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
    Corell A, Ferreyra Vega S, Hoefling N, Carstam L, Smits A, Olsson Bontell T, Björkman-Burtscher IM, Carén H, Jakola AS.
    BMC Cancer; 2020 May 20; 20(1):450. PubMed ID: 32434559
    [Abstract] [Full Text] [Related]

  • 20. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
    Wang J, Yan L, Ai P, He Y, Guan H, Wei Z, He L, Mu X, Liu Y, Peng X.
    Neurosurg Rev; 2021 Jun 20; 44(3):1447-1455. PubMed ID: 32529528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.